Login to Your Account

Merck, KineMed Collaborate On Atherosclerosis In RCT Deal

By Jennifer Boggs

Wednesday, August 8, 2007
KineMed Inc. granted Merck & Co. Inc. nonexclusive rights to identify and develop up to 10 compounds for atherosclerosis using its reverse cholesterol transport (RCT) technology, in exchange for more than $5.5 million in initial and research payments and up to $70 million in milestones per compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription